Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type2 diabetes mellitus

Diabetic Medicine

Volumn 29, Issue 3, 2012, Pages 313-320

  Davies, M J ^a   Chubb, B D ^b   Smith, I C ^b   Valentine, W J ^c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b Novo Nordisk Ltd   (United Kingdom)

^c Ossian Health Economics and Communications   (Switzerland)

Author keywords

Cost effectiveness; Liraglutide; Type2 diabetes; UK

Indexed keywords

GLIMEPIRIDE; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; LIFE EXPECTANCY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PYRAZINES; QUALITY-ADJUSTED LIFE YEARS; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 84857268752     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03429.x     Document Type: Article

References (26)

1. World Health Organization. Diabetes. Fact sheet no. 312. 2009. Available at Last accessed 14 January 2011.
2. Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of type II diabetes. Diabetologia 2002; 45: S13-S17.
3. Koopmanschap M. Coping with type II diabetes: the patient's perspective. Diabetologia 2002; 45: S18-S22.
4. National Collaborating Centre for Chronic Conditions. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (update). London: Royal College of Physicians, 2008.
5. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321: 405-412.
6. National Institute for Health and Clinical Excellence. Type 2 Diabetes: Newer Agents for Blood Glucose Control in Type 2 Diabetes. 2009. Available at Last accessed 14 January 2011.
7. National Institute for Health and Clinical Excellence. Final Appraisal Determination. Liraglutide for the Treatment of Type 2 Diabetes. 2010. Available at Last accessed 14 January 2011.
8. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009; 32: 193-203.
9. White J. Efficacy and safety of incretin-based therapies: clinical trial data. J Am Pharm Assoc 2009; 49: S30-S40.
10. Nauck MA, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH et al., LEAD-2 Study Group Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care 2009; 32: 84-90.
11. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S et al., for the 1860-LIRA-DPP-4 Study Group Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447-1456.
12. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of intervention in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin 2004; 20: S5-S26.
13. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004; 20: S27-S40.
14. National institute for Health and Clinical Excellence. Measuring Effectiveness and Cost Effectiveness: the QALY. 2010. Available at Last accessed 14 January 2011.
15. Haymarket Publications. Monthly Index of Medical Specialities (MIMS), August 2009 edition. London: Haymarket Publications, 2009.
16. National institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. 2008. Available at Last accessed 27 March 2011.
17. Tarn T, Smith M. Pharmacoeconomic guidelines around the world. ISPOR Connections 2004; 10: 5-15.
18. National Institute for Clinical Excellence. Guidance on the Use of Long-Acting Insulin Analogues for the treatment of Diabetes - Insulin Glargine (TA53). 2002. Available at Last accessed 14 January 2011.
19. Russell-Jones D, Nauck M, Brandle M, Vaag A, Colagiuri S, Schmitz O et al. The once-daily human GLP-1 analogue liraglutide reduces body weight in subjects with type 2 diabetes, irrespective of body mass index at baseline. Diabetes 2006; 57: A593.
20. Brod M, Cobden D, Lammert M, Bushnell D, Raskin P. Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. Health Qual Life Outcomes 2007; 5: 8.
21. Jacobs van der Bruggen MAM, Van Baal PH, Hoogenveen RT, Feenstra TL, Briggs AH, Lawson K et al. Cost-effectiveness of lifestyle modification in diabetic patients. Diabetes Care 2009; 32: 1453-1458.
22. Gillett M, Dallosso HM, Brennan A, Carey ME, Campbell MJ, Heller S et al. Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost-effectiveness analysis. Br Med J 2010; 341: c4093.
23. Valentine WJ, Bottmley JM, Palmer AJ, Brändle M, Foos V, Williams R et al. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. Diabet Med 2007; 24: 982-1002.
24. Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab 2008; 10: S43-S55.
25. Ebrahim S, Davey Smith G, McCabe C, Payne N, Pickin M, Sheldon TA et al. What role for statins? A review and economic model. Health Technol Assess 1999; 3: i-iv 1-91.
26. Scottish Diabetes Survey Monitoring Group. Scottish Diabetes Survey 2007. 2007. Available at Last accessed 14 January 2011.